By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Galectin Therapeutics 

7 Wells Avenue, Suite #34

Newton  Massachusetts  02459  U.S.A.
Phone: 617-559-0033 Fax: 617-928-3450


Company News
Galectin Therapeutics Announces Details Of The Design Of Its Phase 2 Program With GR-MD-02 2/24/2015 7:16:56 AM
Final Phase 1 Trial Results Demonstrate Galectin Therapeutics' GR-MD-02 Is Safe With Potential For Therapeutic Effect On Fibrosis In NASH Patients With Advanced Fibrosis 1/7/2015 7:22:17 AM
Galectin Therapeutics To Present At 7th Annual LD Micro Main Event Conference 12/4/2014 3:48:48 PM
Galectin Therapeutics Reports Third Quarter 2014 Financial Results And Provides Update On Company's Development Program 11/10/2014 8:04:41 AM
Galectin Therapeutics' Phase 1 Data Presented At American Association for Study of Liver Diseases Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development 11/10/2014 7:26:20 AM
Galectin Therapeutics' Abstract Accepted As Oral Presentation At The Liver Meeting(R), Annual Meeting Of The American Association For The Study Of Liver Diseases 10/2/2014 7:44:27 AM
Galectin Therapeutics Elects Gilbert S. Omenn, M.D., Ph.D., A Leading Cancer Researcher, To Its Board Of Directors 9/24/2014 7:36:21 AM
Galectin Therapeutics Announces Issuance Of U.S. Patent For GR-MD-02 In Diabetic Nephropathy 9/15/2014 8:02:00 AM
Galectin Therapeutics To Present At Aegis Capital Corporation 2014 Healthcare And Technology Conference 9/10/2014 7:53:49 AM
Galectin Therapeutics Reports Second Quarter 2014 Financial Results 8/8/2014 10:53:36 AM